2026-10-03——
Recursion disclosed TxFM License Agreement with Tempus AI for US$12,000,000 and pathology data
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On 3 October 2026, Simply Wall St reported that Recursion Pharmaceuticals disclosed a past TxFM License Agreement with Tempus AI granting a two year, non exclusive, oncology focused RNA model license for US$12,000,000, together with access to de identified pathology records with linked clinical data.
What happened
- Disclosure surfaced in a Simply Wall St article dated October 03, 2026.
- The agreement is described as a TxFM License Agreement between Recursion Pharmaceuticals and Tempus AI.
- Licence terms: two year, non exclusive, oncology focused RNA model licence for US$12,000,000.
- Recursion receives access to de identified pathology records with linked clinical data.
- Simply Wall St describes the deal as incremental rather than a major short term catalyst, against an analyst narrative pointing to US$220.9 million in revenue by 2028.
Sources
- simplywall.st — primary
- companiesmarketcap.com — party background
- tipranks.com — party background
- stockanalysis.com — party background
- sec.gov — party background
Announced 2026-10-03